MECHELEN, Belgium, February 20, 2013 /PRNewswire/ -- PR Newswire UK (press release) Bendamustine is currently licensed for use after rituximab, an application has been made on the basis of this data for first line use. Results from the StiL NHL-1 study published in the Lancet today show that a first-line treatment regimen of ... |
